BUZZ- Correvio jumps after FDA allows resubmission of marketing application

** U.S.-listed shares of Canadian drugmaker jump 37 pct to $2.85 after FDA agrees to allow resubmission of marketing application for heart drug

** Stock is second among top advancers across U.S. exchanges

** Correvio formerly known as Cardiome Pharma says FDA also agrees to schedule a pre-marketing application meeting and expects it to take place in Q4

** Co’s heart drug Brinavess is approved for marketing in Europe and Canada

** Canada-listed shares also jumped nearly 42 pct

** Including sessions gains, U.S.-listed shares have nearly doubled in value YTD (Reporting by Shreyashi Sanyal in Bengaluru)